| Literature DB >> 26121035 |
Anna Oksuzyan1, Maria Shkolnikova2, James W Vaupel3, Kaare Christensen4, Vladimir M Shkolnikov5.
Abstract
BACKGROUND: The apparent contradiction that women live longer but have worse health than men, the so called male-female health-survival paradox, is very pronounced in Russia. The present study investigates whether men in Moscow are healthier than women at the level of biomarkers, and whether the associations between biomarkers and subjective health have sex-specific patterns. MATERIALS: Previously collected data in the study of Stress, Aging, and Health in Russia (SAHR, n = 1800) were used to examine sex differences in biomarkers and their associations with physical functioning and self-rated health.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26121035 PMCID: PMC4484801 DOI: 10.1371/journal.pone.0131691
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Cutoff values defining high-risk levels of biomarkers.
| Biomarker | Cutoff level |
|---|---|
| Total cholesterol | > = 6.216 mmol/l |
| High density lipoproteins | <1.036 mmol/l |
| Triglycerides | > = 2.26 mmol/l |
| Obesity | > = 30.0 |
| Waist circumference | >102 cm men, >88 cm women |
| Hypertension Grade 1 | Systolic blood pressure > = 140 mm Hg or diastolic blood pressure > = 90 mmHg or anti-hypertensive drug use |
| Hypertension Grade 2 | Systolic blood pressure > = 160 mm Hg or diastolic blood pressure > = 100 mmHg or anti-hypertensive drug use |
| Glycosylated hemoglobin | >6.5% |
| C-reactive protein | > 3 mg/dl |
| Interleukin-6 | > = 2.16 pg/mL men, > = 1.84 mg/dl women |
| Fibrinogen | > = 4.43 g/L men, > = 4.42 g/L women |
| Major Q-wave with a high probability of myocardial infarction | Minnesota codes: 1-1-1 to 1-1-7 and 1-2-1 to 1-2-7 |
| Atrial fibrillation or atrial flutter | Minnesota codes: 8-3-1 to 8-3-4 |
| Left ventricular hypertension with ST-T segment abnormalities | Minnesota codes 3–1 and 3–3 |
a) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
b) NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res 1998;6:51S-209S.
c) WHO. Waist circumference and waist-hip ratio: Report of a WHO expert consultation, Geneva 2011: World Health Organization.
d) Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–2219.
e) Rodbard H, Blonde L, Braithwaite S, Brett E, Cobin R, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Management of Diabetes Mellitus. Endocrine Practice 2007; 13: 1–68.
f) Pearson TA, Mensah GA, Alexander RW, et al. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511.
g) Defined by the highest quintile of the sex-specific distribution.
h) Prineas RJ, Crow RS, Zhang Z-M. The Minnesota Code Manual of Electrocardiographic Findings. London: Springer-Verlag London New York; 2010.
Descriptive statistics of poor physical functioning and poor self-rated health.
| Men | Women | ||||||
|---|---|---|---|---|---|---|---|
| Age | No | % | SE | No | % | SE | p-value |
|
| |||||||
| 55–64 | 284 | 5.63 | 1.37 | 345 | 9.57 | 1.58 | >0.05 |
| 65–74 | 319 | 12.54 | 1.85 | 445 | 22.92 | 1.99 | <0.001 |
| 75+ | 229 | 34.06 | 3.13 | 168 | 47.62 | 3.85 | 0.006 |
| Total | 832 | 16.11 | 1.27 | 958 | 22.44 | 1.35 | 0.001 |
| ASP | 832 | 13.00 | 1.18 | 958 | 20.73 | 1.35 | <0.001 |
|
| |||||||
| 55–64 | 285 | 10.18 | 1.79 | 346 | 16.18 | 1.98 | 0.028 |
| 65–74 | 322 | 11.49 | 1.78 | 447 | 20.36 | 1.90 | 0.001 |
| 75+ | 229 | 26.64 | 2.92 | 168 | 39.88 | 3.78 | 0.005 |
| Total | 836 | 15.19 | 1.24 | 961 | 22.27 | 1.34 | <0.001 |
| ASP | 836 | 13.59 | 1.18 | 961 | 21.82 | 1.35 | <0.001 |
a: SE—standard error, ASP–age–standardized prevalence
b: p–value for sex difference in the prevalence of poor physical functioning and poor self-rated health
Prevalence of high-risk levels of biomarkers.
| Men | Women | ||||||
|---|---|---|---|---|---|---|---|
| Age | No | % | SE | No | % | SE | p-value |
|
| |||||||
|
| |||||||
| Total | 837 | 66.19 | 1.64 | 961 | 19.46 | 1.28 | <0.001 |
| ASP | 837 | 68.35 | 1.65 | 961 | 22.04 | 1.42 | <0.001 |
|
| |||||||
| Total | 804 | 21.64 | 1.45 | 826 | 1.21 | 0.38 | <0.001 |
| ASP | 804 | 23.96 | 1.62 | 826 | 1.49 | 0.47 | <0.001 |
|
| |||||||
| Total | 741 | 24.56 | 1.58 | 831 | 3.97 | 0.68 | <0.001 |
| ASP | 741 | 25.25 | 1.69 | 831 | 4.03 | 0.71 | <0.001 |
|
| |||||||
|
| |||||||
| Total | 839 | 27.77 | 1.55 | 958 | 49.58 | 1.62 | <0.001 |
| ASP | 839 | 29.25 | 1.67 | 958 | 49.41 | 1.69 | <0.001 |
|
| |||||||
| Total | 838 | 31.03 | 1.60 | 957 | 15.67 | 1.18 | <0.001 |
| ASP | 838 | 31.61 | 1.70 | 957 | 16.67 | 1.29 | <0.0001 |
|
| |||||||
| Total | 839 | 9.30 | 1.00 | 958 | 8.56 | 0.90 | >0.05 |
| ASP | 839 | 10.22 | 1.14 | 958 | 9.31 | 1.01 | >0.05 |
|
| |||||||
| Total | 838 | 27.09 | 1.54 | 959 | 43.48 | 1.60 | <0.001 |
| ASP | 838 | 28.92 | 1.67 | 959 | 43.99 | 1.68 | <0.001 |
|
| |||||||
| Total | 835 | 32.34 | 1.62 | 959 | 58.08 | 1.59 | <0.001 |
| ASP | 835 | 32.42 | 1.71 | 959 | 59.44 | 1.65 | <0.001 |
|
| |||||||
| Total | 839 | 54.11 | 1.72 | 961 | 55.25 | 1.60 | >0.05 |
| ASP | 839 | 53.50 | 1.82 | 961 | 53.57 | 1.67 | >0.05 |
|
| |||||||
| Total | 839 | 70.68 | 1.57 | 961 | 68.26 | 1.50 | >0.05 |
| ASP | 839 | 69.11 | 1.70 | 961 | 66.80 | 1.59 | >0.05 |
|
| |||||||
| Total | 832 | 15.75 | 1.26 | 953 | 16.79 | 1.21 | >0.05 |
| ASP | 832 | 15.53 | 1.32 | 953 | 16.71 | 1.27 | >0.05 |
|
| |||||||
|
| |||||||
| Total | 830 | 28.92 | 1.57 | 947 | 28.93 | 1.47 | >0.05 |
| ASP | 830 | 28.77 | 1.65 | 947 | 29.10 | 1.55 | >0.05 |
|
| |||||||
| Total | 833 | 20.17 | 1.39 | 955 | 20.21 | 1.30 | >0.05 |
| ASP | 833 | 19.50 | 1.43 | 955 | 20.62 | 1.36 | >0.05 |
|
| |||||||
| Total | 836 | 20.45 | 1.40 | 957 | 20.17 | 1.30 | >0.05 |
| ASP | 836 | 20.30 | 1.47 | 957 | 20.10 | 1.36 | >0.05 |
|
| |||||||
|
| |||||||
| Total | 839 | 6.67 | 0.86 | 961 | 4.27 | 0.65 | <0.05 |
| ASP | 839 | 6.42 | 0.88 | 961 | 4.13 | 0.66 | <0.05 |
|
| |||||||
| Total | 839 | 5.24 | 0.77 | 961 | 3.43 | 0.59 | >0.05 |
| ASP | 839 | 4.42 | 0.68 | 961 | 3.16 | 0.55 | >0.05 |
|
| |||||||
| Total | 839 | 3.34 | 0.62 | 961 | 1.35 | 0.37 | <0.01 |
| ASP | 839 | 3.18 | 0.62 | 961 | 1.33 | 0.38 | <0.01 |
|
| |||||||
|
| |||||||
| Total | 835 | 9.70 | 1.02 | 959 | 6.05 | 0.77 | <0.01 |
| ASP | 835 | 8.54 | 0.96 | 959 | 5.54 | 0.73 | <0.05 |
|
| |||||||
| Total | 835 | 14.73 | 1.23 | 960 | 5.31 | 0.72 | <0.001 |
| ASP | 835 | 12.98 | 1.15 | 960 | 5.22 | 0.73 | <0.001 |
|
| |||||||
| Total | 834 | 21.46 | 1.42 | 959 | 27.32 | 1.44 | <0.01 |
| ASP | 834 | 18.35 | 1.29 | 959 | 26.13 | 1.40 | <0.001 |
a: ASP–age-standardized prevalence (based on the standard European population), SE–standard error, HDL—high density lipoproteins, Hb–hemoglobin, CRP—C-reactive protein, IL-6—interleukin-6, MI–myocardial infarction, Major Q-wave–Major Q-wave abnormalities with high MI probability, AF–atrial fibrillation or atrial flutter, LVH-ST—Left ventricular hypertrophy plus ST-T abnormalities.
Association of physical functioning with biomarker levels in total and sex-specific samples.
| TOTAL SAMPLE | MEN | WOMEN | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | SE | p-value | OR | SE | p-value | OR | SE | p-value | |
|
| |||||||||
| Women | 1.88 | 0.25 | <0.001 | ||||||
|
| |||||||||
|
| |||||||||
|
| 0.98 | 0.15 | >0.05 | 0.98 | 0.25 | >0.05 | 1.07 | 0.19 | >0.05 |
| Women | 2.04 | 0.37 | <0.001 | ||||||
|
| 1.56 | 0.26 | 0.008 | 1.80 | 0.42 | 0.011 | 1.43 | 0.35 | >0.05 |
| Women | 2.15 | 0.39 | <0.001 | ||||||
|
| 1.71 | 0.42 | 0.028 | 1.36 | 0.52 | >0.05 | 2.23 | 0.70 | 0.010 |
| Women | 2.04 | 0.36 | <0.001 | ||||||
|
| 1.70 | 0.25 | <0.001 | 1.43 | 0.35 | >0.05 | 1.91 | 0.35 | <0.001 |
| Women | 1.87 | 0.34 | 0.001 | ||||||
|
| 1.67 | 0.25 | <0.001 | 1.32 | 0.30 | >0.05 | 1.88 | 0.36 | 0.001 |
| Women | 1.74 | 0.32 | 0.002 | ||||||
|
| 1.24 | 0.20 | >0.05 | 1.03 | 0.25 | >0.05 | 1.38 | 0.28 | >0.05 |
| Women | 2.03 | 0.36 | <0.001 | ||||||
|
| 1.38 | 0.20 | 0.027 | 1.40 | 0.31 | >0.05 | 1.37 | 0.25 | >0.05 |
| Women | 2.01 | 0.36 | <0.001 | ||||||
|
| 1.20 | 0.22 | >0.05 | 1.08 | 0.31 | >0.05 | 1.31 | 0.31 | >0.05 |
| Women | 2.11 | 0.38 | <0.001 | ||||||
|
| |||||||||
|
| 1.81 | 0.27 | <0.001 | 1.80 | 0.43 | 0.012 | 1.68 | 0.32 | 0.007 |
| Women | 1.90 | 0.35 | <0.001 | ||||||
|
| 1.56 | 0.26 | 0.007 | 2.17 | 0.53 | 0.002 | 1.17 | 0.26 | >0.05 |
| Women | 1.97 | 0.35 | <0.001 | ||||||
|
| 1.79 | 0.30 | <0.001 | 2.22 | 0.55 | 0.001 | 1.52 | 0.33 | 0.052 |
| Women | 1.96 | 0.35 | <0.001 | ||||||
|
| |||||||||
|
| 1.31 | 0.39 | >0.05 | 2.98 | 1.13 | 0.004 | 0.50 | 0.26 | >0.05 |
| Women | 2.04 | 0.36 | <0.001 | ||||||
|
| 1.20 | 0.40 | >0.05 | 0.74 | 0.36 | >0.05 | 1.87 | 0.88 | >0.05 |
| Women | 2.03 | 0.36 | <0.001 | ||||||
|
| 1.39 | 0.62 | >0.05 | 0.74 | 0.49 | >0.05 | 3.26 | 2.25 | >0.05 |
| Women | 2.05 | 0.37 | <0.001 | ||||||
|
| |||||||||
|
| 2.21 | 0.53 | 0.001 | 2.02 | 0.66 | 0.033 | 2.54 | 0.87 | 0.006 |
| Women | 2.06 | 0.37 | <0.001 | ||||||
|
| 2.01 | 0.46 | 0.002 | 2.04 | 0.57 | 0.010 | 1.63 | 0.62 | >0.05 |
| Women | 2.12 | 0.38 | <0.001 | ||||||
|
| 2.78 | 0.42 | <0.001 | 3.18 | 0.77 | <0.001 | 2.75 | 0.52 | <0.001 |
| Women | 1.83 | 0.33 | 0.001 | ||||||
a: Model 1 includes sex, age, and quadratic age; Model 2: Model 1 plus biomarker (each separately), smoking status, frequency of current alcohol consumption, and presence of alcohol problems in the past
b: HDL—high density lipoproteins, Hb–hemoglobin, CRP—C-reactive protein, IL-6—interleukin-6, MI–myocardial infarction, Major Q-wave–Major Q-wave abnormalities with high MI probability, AF–atrial fibrillation or atrial flutter, LVH-ST—Left ventricular hypertrophy plus ST-T abnormalities, OR–odds ratio, CI–confidence interval.
Association of poor self-rated health with biomarker levels in the total and sex-specific samples.
| TOTAL SAMPLE | MEN | WOMEN | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | SE | p-value | OR | SE | p-value | OR | SE | p-value | |
|
| |||||||||
| Women | 1.80 | 0.23 | <0.001 | ||||||
|
| |||||||||
|
| |||||||||
|
| 1.10 | 0.16 | >0.05 | 1.21 | 0.29 | >0.05 | 1.15 | 0.20 | >0.05 |
| Women | 1.79 | 0.32 | 0.001 | ||||||
|
| 1.33 | 0.23 | >0.05 | 1.16 | 0.28 | >0.05 | 1.47 | 0.35 | >0.05 |
| Women | 1.88 | 0.34 | <0.001 | ||||||
|
| 1.50 | 0.36 | >0.05 | 1.39 | 0.52 | >0.05 | 1.62 | 0.49 | >0.05 |
| Women | 1.83 | 0.33 | 0.001 | ||||||
|
| 1.53 | 0.22 | 0.004 | 1.73 | 0.41 | 0.022 | 1.47 | 0.26 | 0.028 |
| Women | 1.71 | 0.31 | 0.003 | ||||||
|
| 1.37 | 0.20 | 0.031 | 1.19 | 0.27 | >0.05 | 1.43 | 0.26 | 0.049 |
| Women | 1.68 | 0.31 | 0.004 | ||||||
|
| 1.15 | 0.18 | >0.05 | 0.85 | 0.20 | >0.05 | 1.34 | 0.27 | >0.05 |
| Women | 1.84 | 0.33 | 0.001 | ||||||
|
| 1.39 | 0.20 | 0.023 | 1.29 | 0.29 | >0.05 | 1.43 | 0.26 | 0.053 |
| Women | 1.83 | 0.33 | 0.001 | ||||||
|
| 1.59 | 0.28 | 0.008 | 1.48 | 0.41 | >0.05 | 1.59 | 0.36 | 0.038 |
| Women | 1.90 | 0.34 | <0.001 | ||||||
|
| |||||||||
|
| 1.38 | 0.21 | 0.035 | 1.05 | 0.26 | >0.05 | 1.54 | 0.29 | 0.020 |
| Women | 1.78 | 0.32 | 0.001 | ||||||
|
| 1.69 | 0.28 | 0.001 | 2.44 | 0.59 | <0.001 | 1.15 | 0.25 | >0.05 |
| Women | 1.78 | 0.32 | 0.001 | ||||||
|
| 1.66 | 0.27 | 0.002 | 1.54 | 0.40 | >0.05 | 1.80 | 0.37 | 0.004 |
| Women | 1.82 | 0.33 | 0.001 | ||||||
|
| |||||||||
|
| 1.28 | 0.38 | >0.05 | 2.33 | 0.89 | 0.027 | 0.64 | 0.32 | >0.05 |
| Women | 1.85 | 0.33 | 0.001 | ||||||
|
| 1.96 | 0.60 | 0.028 | 2.32 | 0.91 | 0.032 | 1.45 | 0.68 | >0.05 |
| Women | 1.86 | 0.33 | <0.001 | ||||||
|
| 1.66 | 0.71 | >0.05 | 1.73 | 0.93 | >0.05 | 1.67 | 1.12 | >0.05 |
| Women | 1.87 | 0.33 | <0.001 | ||||||
|
| |||||||||
|
| 2.30 | 0.54 | <0.001 | 2.83 | 0.88 | 0.001 | 1.58 | 0.55 | >0.05 |
| Women | 1.86 | 0.33 | 0.001 | ||||||
|
| 1.93 | 0.44 | 0.004 | 2.11 | 0.59 | 0.007 | 1.73 | 0.63 | >0.05 |
| Women | 1.92 | 0.34 | <0.001 | ||||||
|
| 3.09 | 0.47 | <0.001 | 3.26 | 0.78 | <0.001 | 3.31 | 0.63 | <0.001 |
| Women | 1.66 | 0.30 | 0.005 | ||||||
a: Model 1 includes sex, age, and quadratic age; Model 2: Model 1 plus biomarker (each separately), smoking status, current alcohol consumption, and presence of alcohol problems in the past.
b: HDL—high density lipoproteins, Hb–hemoglobin, CRP—C-reactive protein, IL-6—interleukin-6, MI–myocardial infarction, Major Q-wave–Major Q-wave abnormalities with high MI probability, AF–atrial fibrillation or atrial flutter, LVH-ST—Left ventricular hypertrophy plus ST-T abnormalities, OR–odds ratio, CI–confidence interval.